젠프렉스GNPX 주가

♻️ 재탕[8-K] 중대 사건 — FORM 8-K

♻️ 재탕Genprex Showcases Positive Preclinical Data On Its Diabetes Gene Therapy Drug Candidate At 2026 American Society Of Gene And Cell Therapy Annual Meeting

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four WeeksAUSTIN, Texas, May 14, 2026 /PRNewswire/ -- Genprex, Inc. , a clinical-stage gene therapy company focused on...

[8-K] 중대 사건 — FORM 8-K

Genprex : ASGCT 2026 Poster - Pancreatic Delivery of AAV-Pdx1/MafA Reverses Hyperglycemia in a Preclinical Model of Type 2 Diabetes

Introduction Type 2 diabetes is a major public-health and economic burden with no current cure,...

Genprex Q1 EPS $(0.64) Up From $(13.00) YoY

Genprex (NASDAQ:GNPX) reported quarterly losses of $(0.64) per share. This is a 95.08 percent increase over losses of $(13.00) per share from the same period last year.

[10-Q] 분기 실적 — FORM 10-Q

[SCHEDULE 13G/A] SCHEDULE 13G/A

Top 3 Health Care Stocks That Are Set To Fly In Q2

The health care sector has oversold stocks with RSI below 30, presenting an opportunity for traders to buy undervalued companies.

[8-K] 중대 사건 — FORM 8-K